echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Jew Therapeutics announced that its cellular immunotherapy drugs have successfully benefited 300 patients

    Jew Therapeutics announced that its cellular immunotherapy drugs have successfully benefited 300 patients

    • Last Update: 2023-01-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    SHANGHAI, Nov.
    9, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cellular immunotherapy products, announced that as of November 8, 2022, its cellular immunotherapy drugs (including marketed products and drug candidates) have successfully completed the infusion therapy (both clinical research and commercialization stages) for 300 patients.
    There is hope
    for a cure for these patients and their families.

    WuXi JW has successfully built a world-class cell immunotherapy technology and product development platform, as well as a product pipeline covering hematological and solid tumors, and has carried out 9 clinical studies
    for hematological and solid tumors.
    As JW Therapeutics' first product and a Class 1 new CAR-T product, Tenoda ® (relmacel injection) achieved the first patient infusion treatment in December 2017 and was approved by the National Medical Products Administration of China in September 2021
    In addition, JW Therapeutics has initiated clinical studies
    for solid tumors such as advanced hepatocellular carcinoma this year.

    Yiping Li, co-founder, chairman and CEO of JW Therapeutics, said, "Serving patients is JW Therapeutics' original intention
    Thank you to regulators, researchers, healthcare workers, business partners and others for working with us to serve patients
    We will continue to introduce and develop more cutting-edge technologies, advance product pipelines, reduce production costs, and bring hope for healing to every patient

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.